Get the Stockscreener App
8.31
1.07%
-0.09
After Hours:
8.31
Oric Pharmaceuticals Inc stock is traded at $8.31, with a volume of 1.15M.
It is down -1.07% in the last 24 hours and up +1.96% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$8.40
Open:
$8.39
24h Volume:
1.15M
Relative Volume:
0.62
Market Cap:
$860.23M
Revenue:
-
Net Income/Loss:
$-135.21M
P/E Ratio:
-5.8067
EPS:
-1.4311
Net Cash Flow:
$-114.35M
1W Performance:
+3.88%
1M Performance:
+1.96%
6M Performance:
-8.88%
1Y Performance:
-11.69%
1-Day Range:
$8.085
$8.49
1-Week Range:
$7.455
$8.50
52-Week Range:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.31 | 869.55M | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN
ORIC Pharmaceuticals (ORIC) Gains on Buy Rating from Stifel Amid Positive Trial Outlook - GuruFocus
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC) - GuruFocus
Stifel initiates Oric Pharmaceuticals stock with buy rating By Investing.com - Investing.com Nigeria
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway - TradingView
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
ORIC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma - Traders Union
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth - Streetwise Reports
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals stock falls 6.48% amid bearish momentum as Oric Pharmaceuticals honors cancer survivors - Traders Union
Oric Pharmaceuticals (ORIC) Sheds 6.5% as Shares Test Key Support LevelsUp Down Volume - newsline.com
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
ORIC Pharmaceuticals grants inducement equity to new hires - scanx.trade
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new ORIC hires receive stock options and RSU awards - Stock Titan
Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15 - Moomoo
Oric Pharmaceuticals stock under sustained selling pressure, trades near new support zone - Traders Union
This ORIC Pharmaceuticals Insider Increased Their Holding In The Last Year - Moomoo
ORIC Pharmaceuticals (ORIC) Stock Analysis Report | Financials & Insights - Benzinga España
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Oncology company ORIC plans June talks at Jefferies, Goldman events - Stock Titan
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC Stock Chart | ORIC PHARMACEUTICALS INC (NASDAQ:ORIC) - ChartMill
Trading Systems Reacting to (ORIC) Volatility - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Q1 2026 Earnings: Narrower-Than-Expected Loss, Pipeline Progress Keeps Focus on Key MilestonesEPS Guidance Update - newsline.com
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
User - The Chronicle-Journal
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan
Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada
Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus
Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus
Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Feb 24 '26 |
Sale |
13.51 |
52,000 |
702,686 |
68,148 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):